Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 15/20 | 0.52 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | ELANE | P08246 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3601368 | 0.84 | MAPT (0.45) | KMT2AELANE | |
| SCHEMBL13254021 | 0.79 | PLA2G2A (0.54) | PLA2G2APLA2G1BTSHR | |
| SCHEMBL31219110 | 0.73 | PLA2G2A (0.52) | PLA2G2APLA2G1BKMT2ATSHRMAPK1 | |
| SCHEMBL3587646 | 0.72 | ALDH1A1 (0.46) | KMT2AELANETSHRMAPK1 | |
| SCHEMBL7962081 | 0.72 | PLA2G2A (0.80) | PLA2G2APLA2G1BKMT2ATSHRMAPK1 | |
| SCHEMBL6856097 | 0.71 | PLA2G2A (0.63) | PLA2G2APLA2G1BKMT2ATSHRMAPK1 | |
| SCHEMBL3605317 | 0.71 | ALDH1A1 (0.63) | KMT2ATSHR | |
| SCHEMBL9538311 | 0.70 | CCR2 (0.60) | PLA2G2APLA2G1BKMT2ATSHRMAPK1 | |
| SCHEMBL1504118 | 0.70 | MAPT (0.55) | KMT2ATSHR | |
| SCHEMBL9622481 | 0.70 | NOD2 (0.64) | PLA2G2APLA2G1BKMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100190768-A1 | NOVEL FUSED PYROLE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2010-07-29 | — | — | US | disclosed |
| EP-1930320-A1 | NOVEL FUSED PYRROLE DERIVATIVE | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2008-06-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190768-A1 | NOVEL FUSED PYROLE DERIVATIVE | NR3C1, NR3C2, NR0B1 | PLA2G2A 3533/4885PLA2G1B 3473/4885KMT2A 4721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.